• Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a highly collegial group that is dedicated to the pursuit of excellence and advancement of critical care research in Canada.
  • Canadian Critical Care Trials Group
    The CCCTG has are more than 30 research programs underway and over 100 peer-reviewed publications to its credit, with direct impact on clinical practice in critical care.
  • Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a national organization of more than 300 individuals with research interests in the management of the critically ill patient.
  • Canadian Critical Care Trials Group
    Endorsement by the CCCTG communicates our full commitment to ensure that the work is undertaken in a rigorous and ethical manner, and communicated in a timely and effective way.

Principal Investigator(s)

François Lamontagne, Neill Adhikari


Marie-Hélène Masse
Julie Ménard
Sheila Sprague



View Website

LOVIT : Lessening Organ dysfunction with VITamin C

Treatment options for sepsis are limited to antimicrobials and supportive care (intravenous fluids, vasopressors, mechanical ventilation and renal replacement therapy). Recent preliminary evidence suggests that intravenous vitamin C may be the first therapy to mitigate the dysregulated cascade of events transforming an infection into sepsis. However, definitive practice changing evidence requires a large trial powered to detect a plausible, modest, and clinically important difference in mortality.

LOVIT Trial is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C (50mg/kg/dose during 96 hours) compared to placebo on mortality or persistent organ dysfunction at 28 days in septic intensive care unit patients. This study will be centrally coordinated by the Unité de Recherche Clinique et Épidémiologique (URCE) at the Research Center of the Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), Sherbrooke, QC, Canada.  We will enroll a total of at least 800 patients. Sites are expected to enroll at least 1 patient per month. This trial will be conducted in 25 sites across Canada and at international sites.